

Ref:21-051	Received: 9 February 2021	Issued: 26 February 2021
------------	---------------------------	--------------------------

Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Nov 2020 – Jan 2021

· Adalimumab – Humira	<5
· Adalimumab Biosimilar	54
· Apremilast	22 (Primary care date, Oct – Dec 2020, all conditions)
· Brodalumab	<5
· Certolizumab	<5
· Dimethyl fumarate Skillarence –	15
· Etanercept – Enbrel	0
· Etanercept Biosimilar	<5
· Guselkumab	8
· Infliximab – Remicade	0
· Infliximab Biosimilar	0
· Ixekizumab	<5
· Risankizumab	<5
· Secukinumab	14
· Tildrakizumab	<5
· Ustekinumab	7

Q2. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

· Adalimumab – Humira	<5
· Adalimumab Biosimilar	32
· Golimumab	0
· Infliximab – Remicade	<5
· Infliximab Biosimilar	44
· Tofacitinib	0
· Ustekinumab	21
· Vedolizumab	9

Q3. If possible, could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for Ulcerative Colitis ONLY with the following biologic drugs:

· Adalimumab – Humira	0
· Adalimumab Biosimilar	12
· Golimumab	0
· Infliximab – Remicade	0
· Infliximab Biosimilar	10
· Tofacitinib	0
· Ustekinumab	6
· Vedolizumab	5

Data that is less than five is refused and this could potentially identify individuals and is exempt under section 38(1)(b) of FOISA.